Sarah M Hook

List of Publications by Year
in descending order

104 papers	3,329 citations	147801 31 h-index	175258 52 g-index
106 all docs	106 docs citations	106 times ranked	4313 citing authors

#	Article	IF	Citations
1	Liposomes with cyclodextrin channels and polyethyleneimine (PEI) improves cytoplasmic vaccine delivery and induces anti-cancer immune activity in mice. Journal of Liposome Research, 2022, 32, 22-31.	3.3	6
2	Development of a bioorthogonal fluorescence-based assay for assessing drug uptake and delivery in bacteria. RSC Advances, 2022, 12, 15631-15642.	3.6	0
3	Synthesis and formulation of selfâ€immolative PEG â€aryl azide block copolymers and clickâ€toâ€release reactivity with trans â€cyclooctene. Journal of Polymer Science, 2021, 59, 646-658.	3.8	2
4	Cubosomes enhance drug permeability across the bloodâ€“brain barrier in zebrafish. International Journal of Pharmaceutics, 2021, 600, 120411.	5.2	22
5	Bacteria biohybrid oral vaccines for colorectal cancer treatment reduce tumor growth and increase immune infiltration. Vaccine, 2021, 39, 5589-5599.	3.8	13
6	EGFR-targeted prodrug activation using bioorthogonal alkene-azide click-and-release chemistry. Bioorganic and Medicinal Chemistry, 2021, 46, 116361.	3.0	4
7	Hydrogen Sulfide-Responsive Bicontinuous Nanospheres. Biomacromolecules, 2021, 22, 4770-4782.	5.4	1
8	Lipid-encapsulated oral therapeutic peptide vaccines reduce tumour growth in an orthotopic mouse model of colorectal cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 183-192.	4.3	17
9	Tuning activation and self-immolative properties of the bioorthogonal alkeneâ€“azide click-and-release strategy. Organic and Biomolecular Chemistry, 2020, 18, 4754-4762.	2.8	9
10	Tetrafluoroaryl azide as an N-terminal capping group for click-to-dissolve diphenylalanine hydrogels. RSC Advances, 2020, 10, 9234-9244.	3.6	5
11	Vaccine implants: current status and recent advancements. Emerging Topics in Life Sciences, 2020, 4, 601-612.	2.6	3
12	Utilization of Microfluidics for the Preparation of Polymeric Nanoparticles for the Antioxidant Rutin: A Comparison with Bulk Production. Pharmaceutical Nanotechnology, 2019, 7, 469-483.	1.5	13
13	Microcontainers for protection of oral vaccines, in vitro and in vivo evaluation. Journal of Controlled Release, 2019, 294, 91-101.	9.9	34
14	Alkeneâ€“Azide 1,3â€Dipolar Cycloaddition as a Trigger for Ultrashort Peptide Hydrogel Dissolution. Chemistry - an Asian Journal, 2019, 14, 1143-1150.	3.3	11
15	Poloxamer 407â€chitosan grafted thermoresponsive hydrogels achieve synchronous and sustained release of antigen and adjuvant from singleâ€shot vaccines. Immunology and Cell Biology, 2018, 96, 656-665.	2.3	27
16	Mechanistic Evaluation of Bioorthogonal Decaging with trans-Cyclooctene: The Effect of Fluorine Substituents on Aryl Azide Reactivity and Decaging from the 1,2,3-Triazoline. Bioconjugate Chemistry, 2018, 29, 324-334.	3.6	30
17	Characterization and evaluation of stabilized particulate formulations as therapeutic oral vaccines for allergy. Journal of Liposome Research, 2018, 28, 296-304.	3.3	8
18	Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment. European Journal of Medicinal Chemistry, 2018, 145, 770-789.	5.5	15

#	Article	IF	Citations
19	Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1H)-one-3-carboxamide scaffold. MedChemComm, 2018, 9, 2055-2067.	3.4	14
20	Are phytosomes a superior nanodelivery system for the antioxidant rutin?. International Journal of Pharmaceutics, 2018, 548, 82-91.	5.2	45
21	Spray dried cubosomes with ovalbumin and Quil-A as a nanoparticulate dry powder vaccine formulation. International Journal of Pharmaceutics, 2018, 550, 35-44.	5.2	30
22	Twin-screw extruded lipid implants containing TRP2 peptide for tumour therapy. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 79-87.	4.3	12
23	Stability, Kinetic, and Mechanistic Investigation of 1,8-Self-Immolative Cinnamyl Ether Spacers for Controlled Release of Phenols and Generation of Resonance and Inductively Stabilized Methides. Organic Letters, 2017, 19, 528-531.	4.6	6
24	Preliminary evaluation of a thermosensitive chitosan hydrogel for Echinococcus granulosus vaccine delivery. Veterinary Parasitology, 2017, 236, 117-120.	1.8	11
25	Liposomal Î±-galactosylceramide is taken up by gut-associated lymphoid tissue and stimulates local and systemic immune responses. Journal of Pharmacy and Pharmacology, 2017, 69, 1724-1735.	2.4	6
26	Chemical Tools for Studying Lipid-Binding Class A G Proteinâ€“Coupled Receptors. Pharmacological Reviews, 2017, 69, 316-353.	16.0	20
27	Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor Licofelone. Frontiers in Immunology, 2016, 7, 537.	4.8	9
28	Reasons for use and non-use of the pertussis vaccine during pregnancy: an interview study. Journal of Primary Health Care, 2016, 8, 344.	0.6	23
29	Development of a Multi-Compartmental Oral Vaccine Delivery System. Drug Delivery Letters, 2016, 6, 57-62.	0.5	1
30	Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?. Pharmaceutical Research, 2016, 33, 2078-2097.	3.5	58
31	Chitosan gel vaccine protects against tumour growth in an intracaecal mouse model of cancer by modulating systemic immune responses. BMC Immunology, 2016, 17, 39.	2.2	21
32	Stabilising cubosomes with Tween 80 as a step towards targeting lipid nanocarriers to the bloodâ€“brain barrier. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 104, 148-155.	4.3	84
33	Vaccination of Sheep with a Methanogen Protein Provides Insight into Levels of Antibody in Saliva Needed to Target Ruminal Methanogens. PLoS ONE, 2016, 11, e0159861.	2.5	16
34	Synthesis, Formulation, and Adjuvanticity of Monodesmosidic Saponins with Olenanolic Acid, Hederagenin and Gypsogenin Aglycones, and some C-28 Ester Derivatives. ChemistryOpen, 2015, 4, 740-755.	1.9	7
35	Recent insights into cutaneous immunization: How to vaccinate via the skin. Vaccine, 2015, 33, 4663-4674.	3.8	78
36	First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice. International Journal of Pharmaceutics, 2015, 479, 408-415.	5.2	21

#	Article	IF	Citations
37	Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma. Immunology and Cell Biology, 2015, 93, 634-640.	2.3	30
38	Impact of implant composition of twin-screw extruded lipid implants on the release behavior. International Journal of Pharmaceutics, 2015, 493, 102-110.	5.2	12
39	Selective quantitation of the incorporation of the immunomodulator Î±-galactosylceramide in liposomes using LCâ€“MS/MS. International Journal of Mass Spectrometry, 2015, 392, 96-101.	1.5	4
40	A lipid based multi-compartmental system: Liposomes-in-double emulsion for oral vaccine delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 15-21.	4.3	33
41	Synthetic TRP2 long-peptide and Î±-galactosylceramide formulated into cationic liposomes elicit CD8 + T-cell responses and prevent tumour progression. Vaccine, 2015, 33, 5838-5844.	3.8	34
42	Modified thermoresponsive Poloxamer 407 and chitosan solâ€“gels as potential sustained-release vaccine delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 74-81.	4.3	43
43	Quantitation of the immunological adjuvants, monophosphoryl lipid A and Quil A in poly (lactic-co-glycolic acid) nanoparticles using high performance liquid chromatography with evaporative light scattering detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 975, 45-51.	2.3	10
44	In vivo investigation of twin-screw extruded lipid implants for vaccine delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 338-346.	4.3	13
45	Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants. Immunology and Cell Biology, 2014, 92, 535-542.	2.3	64
46	Physical Characterization of Synthetic Phosphatidylinositol Dimannosides and Analogues in Binary Systems with Phosphatidylcholine. Molecular Pharmaceutics, 2014, 11, 913-921.	4.6	1
47	Dynamic Visualization of Dendritic Cell-Antigen Interactions in the Skin Following Transcutaneous Immunization. PLoS ONE, 2014, 9, e89503.	2.5	23
48	Physicochemical and Biological Characterization of Synthetic Phosphatidylinositol Dimannosides and Analogues. Molecular Pharmaceutics, 2013, 10, 1928-1939.	4.6	6
49	In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations. Vaccine, 2013, 31, 4812-4819.	3.8	64
50	Transcutaneous immunization using microneedles and cubosomes: Mechanistic investigations using Optical Coherence Tomography and Two-Photon Microscopy. Journal of Controlled Release, 2013, 172, 894-903.	9.9	57
51	Community pharmacy influenza immunisation increases vaccine uptake and gains public approval. Australian and New Zealand Journal of Public Health, 2013, 37, 489-490.	1.8	13
52	Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. Journal of Controlled Release, 2013, 165, 16-21.	9.9	98
53	Assessment of transcutaneous vaccine delivery by optical coherence tomography. Laser Physics Letters, 2012, 9, 607-610.	1.4	18
54	Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunisation: characterisation and in vitro skin penetration. Journal of Pharmacy and Pharmacology, 2012, 64, 1560-1569.	2.4	110

#	Article	IF	Citations
55	Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems. Journal of Liposome Research, 2012, 22, 193-204.	3.3	48
56	Modeling the Kinetics of the Immune Response. SIMAI Springer Series, 2012, , 267-282.	0.4	7
57	Smad2:A Candidate Gene for the Murine Autoimmune Diabetes LocusIdd21.1. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E2072-E2077.	3.6	4
58	Preparation of phytantriol cubosomes by solvent precursor dilution for the delivery of protein vaccines. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 15-22.	4.3	145
59	Development and characterisation of modified poloxamer 407 thermoresponsive depot systems containing cubosomes. International Journal of Pharmaceutics, 2011, 408, 20-26.	5.2	66
60	Immuno-stimulating complexes prepared by ethanol injection. Journal of Pharmacy and Pharmacology, 2010, 57, 729-733.	2.4	23
61	Mannosylated liposomes as antigen delivery vehicles for targeting to dendritic cellsâ€. Journal of Pharmacy and Pharmacology, 2010, 58, 729-737.	2.4	78
62	Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery. Journal of Pharmacy and Pharmacology, 2010, 60, 1591-1600.	2.4	46
63	Distribution of fibroblast growth factor-2 (FGF-2) within model excisional wounds following topical application. Journal of Pharmacy and Pharmacology, 2010, 61, 193-200.	2.4	7
64	In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery. European Journal of Pharmaceutical Sciences, 2010, 41, 360-368.	4.0	54
65	Bicontinuous cubic liquid crystals as sustained delivery systems for peptides and proteins. Expert Opinion on Drug Delivery, 2010, 7, 1133-1144.	5.0	112
66	Advances in Lipid-Based Subunit Vaccine Formulations. Current Immunology Reviews, 2009, 5, 42-48.	1.2	23
67	Oral insulin delivery using nanoparticles based on microemulsions with different structure-types: Optimisation and in vivo evaluation. European Journal of Pharmaceutical Sciences, 2009, 37, 53-61.	4.0	57
68	Liquid Crystalline Systems of Phytantriol and Glyceryl Monooleate Containing a Hydrophilic Protein: Characterisation, Swelling and Release Kinetics. Journal of Pharmaceutical Sciences, 2009, 98, 4191-4204.	3.3	107
69	The synthesis and immune stimulating action of mannose-capped lysine-based dendrimers. Tetrahedron, 2009, 65, 2939-2950.	1.9	17
70	Mannosylated saponins based on oleanolic and glycyrrhizic acids. Towards synthetic colloidal antigen delivery systems. Bioorganic and Medicinal Chemistry, 2009, 17, 5207-5218.	3.0	12
71	Phosphatidyl choline-based colloidal systems for dermal and transdermal drug delivery. Journal of Liposome Research, 2009, 19, 267-277.	3.3	22
72	Microemulsions containing lecithin and sugar-based surfactants: Nanoparticle templates for delivery of proteins and peptides. International Journal of Pharmaceutics, 2008, 350, 351-360.	5.2	67

#	Article	IF	Citations
73	Immunostimulatory lipid implants containing Quil-A and DC-cholesterol. International Journal of Pharmaceutics, 2008, 363, 91-98.	5.2	14
74	Protein delivery using nanoparticles based on microemulsions with different structure-types. European Journal of Pharmaceutical Sciences, 2008, 33, 434-444.	4.0	44
75	Immunostimulatory biodegradable implants containing the adjuvant Quil-Aâ€”Part I: Physicochemical characterisation. Journal of Drug Targeting, 2008, 16, 213-223.	4.4	19
76	In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine, 2008, 26, 4549-4556.	3.8	39
77	Immunostimulatory biodegradable implants containing the adjuvant Quil-Aâ€”Part II:In vivoevaluation. Journal of Drug Targeting, 2008, 16, 224-232.	4.4	27
78	Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery. Journal of Pharmacy and Pharmacology, 2008, 60, 1591-1600.	2.4	13
79	The Role of Topical Growth Factors in Chronic Wounds. Current Drug Delivery, 2007, 4, 195-204.	1.6	71
80	Self-Assembled Geometric Liquid-Crystalline Nanoparticles Imaged in Three Dimensions:â€‰ Hexosomes Are Not Necessarily Flat Hexagonal Prisms. Langmuir, 2007, 23, 12461-12464.	3.5	70
81	Cage-like complexes formed by DOTAP, Quil-A and cholesterol. International Journal of Pharmaceutics, 2007, 332, 192-195.	5.2	16
82	Analysis of Quil Aâ€“phospholipid mixtures using drift spectroscopy. International Journal of Pharmaceutics, 2007, 342, 49-61.	5.2	9
83	Characterisation of colloidal drug delivery systems from the naked eye to Cryo-FESEM. Micron, 2007, 38, 796-803.	2.2	35
84	Preparation of poly (alkylcyanoacrylate) nanoparticles by polymerization of water-free microemulsions. Journal of Microencapsulation, 2006, 23, 499-512.	2.8	14
85	Synthetic lipopeptides formulated in liposomes: effect on their immune stimulatory capacity in vitro. , 2006, , .		0
86	Rotavirus hospitalisation in New Zealand children under 3 years of age. Journal of Paediatrics and Child Health, 2006, 42, 196-203.	0.8	21
87	On the preparation, microscopic investigation and application of ISCOMs. Micron, 2006, 37, 724-734.	2.2	50
88	Immunogenicity of Liposomes Containing Lipid Core Peptides and the Adjuvant Quil A. Pharmaceutical Research, 2006, 23, 1473-1481.	3.5	28
89	Critical role of preproenkephalin in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2006, 179, 18-25.	2.3	12
90	Immunostimulatory colloidal delivery systems for cancer vaccines. Expert Opinion on Drug Delivery, 2006, 3, 345-354.	5.0	44

#	Article	IF	Citations
91	Quil Aâ€“lipid powder formulations releasing ISCOMs and related colloidal stuctures upon hydration. Journal of Controlled Release, 2005, 103, 45-59.	9.9	30
92	Using different structure types of microemulsions for the preparation of poly(alkylcyanoacrylate) nanoparticles by interfacial polymerization. Journal of Controlled Release, 2005, 106, 76-87.	9.9	70
93	Cationic cage-like complexes formed by DC-cholesterol, Quil-A, and phospholipid. Journal of Pharmaceutical Sciences, 2005, 94, 1794-1807.	3.3	29
94	Lower Airway Inflammation in Infants with Cystic Fibrosis Detected by Newborn Screening. Pediatric Pulmonology, 2005, 40, 500-510.	2.0	205
95	Colocalization of Mouse Autoimmune Diabetes Loci Idd21.1 and Idd21.2 With IDDM6 (Human) and Iddm3 (Rat). Diabetes, 2005, 54, 2820-2825.	0.6	22
96	Bystander suppression of allergic airway inflammation by lung resident memory CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6116-6121.	7.1	67
97	Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipidâ€coreâ€peptides. Immunology and Cell Biology, 2004, 82, 517-522.	2.3	12
98	Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes. Immunology and Cell Biology, 2004, 82, 547-554.	2.3	27
99	Absence of preproenkephalin increases the threshold for T cell activation. Journal of Neuroimmunology, 2003, 140, 61-68.	2.3	10
100	Th2-dependent airway eosinophilia is regulated by preproenkephalin. Journal of Neuroimmunology, 2000, 107, 59-65.	2.3	17
101	Analysis of Two IL-4 Promoter Polymorphisms in a Cohort of Atopic and Asthmatic Subjects. Experimental and Clinical Immunogenetics, 1999, 16, 33-35.	1.2	9
102	Preproenkephalin is a Th2 cytokine but is not required for Th2 differentiationin vitro. Immunology and Cell Biology, 1999, 77, 385-390.	2.3	25
103	Activation of an interleukinâ€4 mRNAâ€producing population of peripheral blood mononuclear cells after infection with Mycobacterium bovis or vaccination with killed, but not live, BCG. Immunology, 1996, 88, 269-274.	4.4	28
104	Cloning and Expression of the Cervine Interleukin 4 Gene. Scandinavian Journal of Immunology, 1994, 40, 71-76.	2.7	11